Calidi Biotherapeutics, Inc. (CLDI)
- Previous Close
0.4973 - Open
0.4924 - Bid 0.4902 x 1200
- Ask 0.4998 x 900
- Day's Range
0.4700 - 0.5097 - 52 Week Range
0.3500 - 4.9000 - Volume
35,788 - Avg. Volume
1,193,490 - Market Cap (intraday)
15.874M - Beta (5Y Monthly) 1.19
- PE Ratio (TTM)
-- - EPS (TTM)
-2.9700 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.25
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.
www.calidibio.comRecent News: CLDI
View More
Performance Overview: CLDI
Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLDI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLDI
View MoreValuation Measures
Market Cap
15.81M
Enterprise Value
13.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
10.31
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-112.48%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-23.81M
Diluted EPS (ttm)
-2.9700
Balance Sheet and Cash Flow
Total Cash (mrq)
9.59M
Total Debt/Equity (mrq)
357.52%
Levered Free Cash Flow (ttm)
-11.21M